APELOA(SZ:000739)2014-03-18 16:00Financial Performance - The company reported a significant increase in revenue, with total revenue reaching 1.5 billion CNY, representing a year-on-year growth of 15%[21]. - The company achieved a net profit of 300 million CNY, reflecting a 10% increase compared to the previous year[21]. - The company's operating revenue for 2013 was ¥3,899,764,834.76, representing a 12.06% increase compared to ¥3,480,088,217.95 in 2012[22]. - The net profit attributable to shareholders for 2013 was ¥167,358,826.37, a 22.04% increase from ¥137,133,177.56 in 2012[22]. - The company achieved a total revenue of CNY 389,976.48 million in 2013, representing an increase of CNY 41,967.66 million or 12.06% compared to the previous year[46]. - The company’s gross profit margin for the pharmaceutical main business was 22.62%, a decrease of 0.52% from the previous year[61]. - The revenue from domestic markets reached CNY 2,471,004,727.77, reflecting a growth of 30.67% year-on-year[64]. - The company reported a significant increase in revenue, with a total of 5 billion RMB for the year 2013, reflecting a growth of 15% compared to the previous year[138]. Dividend and Profit Distribution - The company proposed a profit distribution plan, distributing a cash dividend of 0.10 CNY per 10 shares and a capital reserve increase of 3 shares per 10 shares[8]. - A cash dividend of CNY 0.1 per share is proposed, along with a capital increase plan[88]. - The cash dividend amount for 2013 was CNY 8,154,557.32, representing 4.87% of the net profit attributable to shareholders[89]. - The total distributable profit for the period was CNY 10,138,230.82, with cash dividends accounting for 100% of the total profit distribution[89]. Research and Development - The company is investing in R&D for new pharmaceutical products, with an allocated budget of 200 million CNY for the upcoming year[21]. - The company invested CNY 109.71 million in R&D in 2013, an increase of CNY 4.09 million from the previous year[39]. - R&D expenditure totaled ¥109.71 million, constituting 6.12% of net assets and 2.81% of operating revenue[69]. - The company plans to enhance product research and development, integrate production, marketing, and management resources, and optimize industry layout[35]. - The company aims to launch three new products in the next quarter, targeting a market size of 500 million CNY[21]. - The company is focusing on developing high-value new products and obtaining necessary certifications for market entry in Europe and the US[84]. - The company plans to invest 200 million RMB in R&D for new technologies in the upcoming year[138]. Market Expansion and Strategy - The company plans to expand its market presence by entering new regions, targeting a 20% increase in market share over the next fiscal year[21]. - The company is gradually expanding its business in anti-infection, cardiovascular, and oncology formulations through industry mergers and acquisitions[35]. - The company has established partnerships with international firms to enhance its technological capabilities, aiming for a 30% improvement in production efficiency[21]. - The company is focusing on market expansion in Southeast Asia, targeting a 25% increase in market share within the next two years[138]. - Future strategies include expanding market share through new product sales channels and leveraging national healthcare policy reforms[84]. Corporate Governance and Compliance - The company emphasizes the importance of compliance and governance, ensuring all operations align with regulatory standards[21]. - The company adheres to strict corporate governance practices in compliance with relevant laws and regulations, ensuring proper internal controls[168]. - The company has established a legal and compliant corporate governance structure, including a shareholder meeting, board of directors, supervisory board, and independent director system[184]. - The company reported no significant deficiencies in internal control during the reporting period[189]. - The audit opinion for the financial statements was a standard unqualified opinion, confirming fair representation of the company's financial status as of December 31, 2013[197]. Asset Management and Financial Stability - The total assets at the end of 2013 were ¥4,662,256,191.02, reflecting a 13.51% increase from ¥4,107,220,717.96 at the end of 2012[22]. - The net assets attributable to shareholders increased by 32.65% to ¥1,792,339,614.71 from ¥1,351,142,066.49 at the end of 2012[22]. - The company reported normal cash flow and good financial status, indicating stability in its operations[129]. - The company’s management team reported a stable cash flow, with a cash reserve of 1.5 billion RMB, ensuring liquidity for future investments[138]. Employee and Management Practices - The total number of employees is 6,049, with 3,971 in production, 795 in technology, 765 in administration, 404 in sales, and 114 in finance[163]. - The company emphasizes performance-based salary adjustments, considering market levels and the company's financial capacity[163]. - The company plans to enhance training for management and technical teams to build a stronger talent pool, focusing on practical and theoretical skills[165]. - The company is exploring a compensation management system that aligns with modern standards, currently maintaining a salary plus bonus structure[155]. - The management team includes experienced professionals with backgrounds in various sectors, enhancing the company's strategic capabilities[156]. Strategic Acquisitions and Partnerships - The company is focusing on strategic acquisitions to enhance its product portfolio, with plans to acquire at least two smaller firms in the next year[21]. - A strategic acquisition was completed in 2013, enhancing the company's product portfolio and expected to generate an additional 300 million RMB in annual revenue[138]. - The company has initiated over 20 contract manufacturing projects to strengthen collaboration with leading international pharmaceutical companies[43]. Shareholder Information - The total number of shares after the recent changes is 815.46 million, with 99.99% being unrestricted shares[111]. - The largest shareholder, Hengdian Group Holdings, held 17.33% of shares, totaling 141,320,990 shares, with 20,000,000 shares pledged[124]. - The company’s shareholding structure showed a diverse range of shareholders, including both domestic and foreign entities[124]. - The top 10 unrestricted shareholders include major institutional investors such as Industrial and Commercial Bank of China, which holds 16,183,100 shares[126].